New psoriasis and cystic fibrosis treatments now on PBS
18 Feb 2026
Wynzora, which contains calcipotriol and betamethasone dipropionate, is now available on the PBS for chronic stable plaque-type psoriasis vulgaris. The cream helps slow the overgrowth of skin cells and reduce redness, itching, and irritation. The listing is expected to benefit around 141,000 patients. Without the subsidy, the treatment costs about $65 per prescription.
The PBS has also expanded access to dapagliflozin (Forxiga) for people living with chronic kidney disease, helping around 65,000 Australians. Without the subsidy, a script costs about $670.
For people with cystic fibrosis, Alyftrek (vanzacaftor with tezacaftor and deutivacaftor) is now on the PBS for patients aged six and older who have at least one CFTR gene mutation that responds to treatment. The oral medication helps increase the amount of functioning CFTR proteins. This follows last year’s PBS listing of Trikafta (elexacaftor/tezacaftor/ivacaftor) and gives more than 2,650 patients access to a treatment that would have cost around $250,000 without subsidy.
Federal Health and Ageing Minister Mark Butler said the changes make previously expensive medicines affordable and accessible for patients who need them.
https://www1.racgp.org.au/
Source: Australian Government – PBS announcements